About the Study

70% of people who suffer from atopic dermatitis have moderate-to-severe atopic dermatitis.

The ARCADIA study is testing the effectiveness of an investigational medication to reduce the symptoms of moderate-to-severe atopic dermatitis in adults and adolescents. The study will recruit approximately 750 people throughout North America, Asia-Pacific, and Europe who have been living with moderate-to-severe atopic dermatitis and itching for at least 2 years.

If a participant’s atopic dermatitis and itching respond to the study treatment, they may be in the study for approximately 60 weeks, visiting the study doctor’s office at least 16 times. If a participant’s atopic dermatitis and itching do not respond to the study treatment, their participation will be approximately 28 weeks, visiting the study doctor’s office at least 8 times.

The investigational medication will be provided to eligible participants at no cost. Participants will receive all study-related doctor visits, laboratory work, tests and procedures at no cost.

Taking part in this study is voluntary, and a participant can choose not to take part or to leave the study at any time.

Arcadia (Greek) refers to any real or imaginary place offering peace and simplicity. A mountainous region of ancient Greece traditionally known for the innocence of its people, Arcadia is a poetic shaped space associated with natural splendor and harmony. This conveys the idea of relief and freedom from symptoms.